








Suppl. Figure S1. Disease course and sNfL of the individual patients (n = 14) receiving CLAD therapy.
- NEDA-3 achieved














- No NEDA-3:







	severe relaps		Cladribine cycle
	relaps		sNfL
	MRI activity		Treatment switch

NEDA: no evidence of disease activity